James Rozsa Partner

James is a corporate lawyer specialising in mergers and acquisitions, private equity transactions and equity capital markets.

He advises clients from a variety of industries including private equity sponsors. He is an expert in all aspects of domestic and cross-border M&A deals including public (takeovers and schemes of arrangements) and privately negotiated transactions and ECM deals including cross-border listings on the ASX.

James is qualified in both Australia and the US, and has for many years advised US clients doing business in Australia and Australian clients doing business in the US.

James has been consistently recognised by his peers (Best Lawyers) for each of M&A (since 2010), Private Equity (since 2010), Corporate & Venture Capital Law (since 2010) and by his clients (Chambers) as a leading individual, again for each of Corporate/M&A, Private Equity (2011-2021) and Capital Markets (2016-2021). In Chambers he is described as “easily the best private equity lawyer we have dealt with, especially on cross-border deals”and is regarded as a "solutions-based lawyer who is very hands-on during a deal" and is lauded for producing "high-quality work quickly and with strong client interaction.”

Experience

Recent private equity experience

Potentia Capital

Acting in relation to its acquisition of Commerce Vision (2021).

Virgin Group

Acting in relation to its investment in the Bain Capital consortium for Virgin Australia (2020).

Archer Capital

Acting in relation to its partial divestment of illion (2020).

Liverpool Partners

Acting in relation to its acquisition of Melbourne IT Consulting (2020).

Potentia Capital

Acting in relation to its portfolio acquisition of Premier Technologies, a payments solution (2020).

Insight Partners

Acting in relation to its acquisition of Kumo Holdings (2020).

Archer Capital

Acting in relation to its proposed acquisition of FunLab (2020).

Potentia Capital

Advised on all corporate aspects of Potentia’s acquisition of 100% of PC-EFTPOS (2019).

Marlin Equity

Acting in relation to its acquisition of HotSchedules (formerly RedBook) (2019).

Archer Capital

Acting in relation to its divestment of LCR Group to Qube (2019).

Coast2Coast

Acting in relation to its divestment of Marlin Brands (2019).

Potentia Capital

Advising on its acquisition of Micromine (2018).

Matrix Partners

Advising on its PIPE into Afterpay (ASX:APT) (2018).

JMI Equity

Advising on its acquisition of Serraview Holdings (2018).

PCI Pharma

Advising on its acquisition of Pharmaceutical Packaging (2018).

Archer Capital

Acting in relation to its divestment of AeroCare to Swissport (2018).

Recent venture capital expereince

Linktree

Advised on series B funding round of financing (2021).

Bioscience Managers

Acting in relation to its investment in Canary (2020).

Felicis Ventures

Advising on its seed investment in Dovetail (2020).

Clean Energy Finance Corporation

Acting in relation to its investment in Sunman energy (2020).

Ten Eleven Ventures

Advising on its Series B investment in Kasada (2020).

Insight Partners

Advised on its Series B investment of Linktree (2020).

Accel-KKR

Advising on its Series A investment in Pegasus Management (2020).

Bioscience Managers

Acting in relation to its investment in Pharmamark (2019).

Replica Media

Advising on its US-redomicile and seed financing (2019).

Cardiac Dimensions

Acting in relation to on its Series B financing (2018).

Blade Therapeutics, Inc.

Advising on the Initial Closing of its US$50 million Series C round of financing (2018).

Madorra

Advising on on its Series A fundraising (2018).

Accel-KKR

Advising on its series A investment in Humanforce, a workplace management solution (2018).

Institutional Venture Partners and OpenView

Advising on their series C investment in Deputy Group (2018).

Inference Technologies

Advising on its investment by Peakspan Capital (2018).

Khosla Ventures

Advising on its seed investment in Popgun Labs (2018).

Brandon Capital Partners and MH Carnegie & Co

Advising on their investment in EBR Systems (2017).

IPO experience

Laybuy Limited (ASX:LBY)

Acting for Laybuy Limited on its pre-IPO and IPO and ASX-listing (2020).

Imricor Medical Systems, Inc (ASX:IMR)

Acting for Imricor Medical Systems on its IPO and ASX-listing (2019).

Visioneering Technologies, Inc (ASX:VTI)

Acting on its IPO and ASX-listing (2017).

AccuVein, Inc

Acting on its proposed IPO and ASX-listing (2017).

AirXpanders, Inc (ASX:AXP)

Acting for AirXpanders on its IPO and ASX-listing (2015).

Recognition

Named lawyer of the year in venture capital law
Best Lawyers, 2021
Ranked as a leading lawyer in corporate/M&A and private equity
Chambers Asia Pacific, 2016-2021
Ranked as a leading lawyer in capital markets: equity
Chambers Asia Pacific Legal, 2016- 2021
James Rozsa is "very strong and commercial across key issues, and is very responsive and able to deal with situations that come up last-minute," according to one client. He frequently acts for clients on IPOs and ASX listings.
Chambers Asia Pacific, 2021
Listed as a leading lawyer in mergers and acquisitions, corporate/governance practice, corporate, equity capital markets, private equity and venture capital law
Best Lawyers, since 2010
One client describes James as "knowledgeable and responsive", adding that "he also understands US law and can help a US company publicly trade in Australia"
Chambers Asia Pacific, 2020
James Rozsa is a "commercial problem solver who holds 'trusted adviser' status"
Chambers Asia Pacific, 2020
James Rozsa has "a great understanding of private equity deals and is always keen to provide innovative solutions”
Chambers Asia Pacific, 2018
James Rozsa is praised for being "very commercial, well-connected and solutions-oriented”
Chambers Asia Pacific, 2017
James Rozsa is ... particularly valued by clients as an adviser with "the rare quality of assessing risk rather than just identifying it and focusing on the stuff that poses genuine problems"
Chambers Asia-Pacific, 2017
James Rozsa is highlighted for his "legal expertise and great professional advice," and also for his "great communication skills and management of investor expectations and concerns"
Chambers Asia-Pacific, 2015
James Rozsa is described as a "solutions-based lawyer who is very hands-on during a deal," and is also lauded for producing "high-quality work quickly and with strong client interaction"
Chambers Asia-Pacific, 2014
James Rozsa is praised by clients for his "tireless work on documentation" and for proving "good in both service and content"
Chambers Asia-Pacific, 2014

Career & qualifications

Qualifications

  • Bachelor of Laws, Sydney University
  • Bachelor of Arts, Sydney University
  • New York State Bar

International experience

  • Qualified in both Australia and the US, James has closed many deals around the world, including in Sydney, New York, London, Milan, Stockholm and Beijing
  • Experience in North America and Europe as an investment banker
  • For many years advised US clients doing business in Australia and Australian clients doing business in the US, including a number of US med-tech companies on their proposed Australian IPOs and ASX-listings

 

Insights Read more insight

Australia’s media reform and its impact on M&A activity

On 16 October 2017, the Broadcasting Legislation Amendment (Broadcasting Reform) Bill 2017 (Cth) was passed by Australia’s House of Representatives and granted Royal assent. Following the Royal...

More
New FIRB Business Exemption Certificates

There are a number of associated issues and uncertainties regarding a new exemption certificate for business acquisitions by foreign investors (Business EC).

More
Transparency on the beneficial ownership of companies

In February 2017, the Australian Government released a consultation paper titled ‘Increasing Transparency of the Beneficial Ownership of Companies’ (Consultation Paper) to explore the potential to...

More